David E. Modrak

868 total citations
21 papers, 715 citations indexed

About

David E. Modrak is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, David E. Modrak has authored 21 papers receiving a total of 715 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 12 papers in Oncology and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in David E. Modrak's work include Glycosylation and Glycoproteins Research (8 papers), Pancreatic and Hepatic Oncology Research (6 papers) and Sphingolipid Metabolism and Signaling (6 papers). David E. Modrak is often cited by papers focused on Glycosylation and Glycoproteins Research (8 papers), Pancreatic and Hepatic Oncology Research (6 papers) and Sphingolipid Metabolism and Signaling (6 papers). David E. Modrak collaborates with scholars based in United States. David E. Modrak's co-authors include David V. Gold, David M. Goldenberg, Thomas M. Cardillo, Robert M. Sharkey, Rosalyn D. Blumenthal, Ralph H. Hruban, Keith Schutsky, Zhiliang Ying, John P. Richardson and Zarir E. Karanjawala and has published in prestigious journals such as Journal of Clinical Oncology, Biochemistry and Cancer Research.

In The Last Decade

David E. Modrak

21 papers receiving 708 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David E. Modrak United States 14 435 303 112 98 92 21 715
Katherine Kravik Norway 9 358 0.8× 306 1.0× 61 0.5× 128 1.3× 32 0.3× 11 652
Yoshiyuki Nishikawa Japan 13 468 1.1× 131 0.4× 52 0.5× 110 1.1× 49 0.5× 28 745
Shou-Ching Tang United States 18 468 1.1× 238 0.8× 49 0.4× 117 1.2× 69 0.8× 37 767
Svein A. Carlsen Canada 15 449 1.0× 300 1.0× 51 0.5× 107 1.1× 25 0.3× 27 723
Annemarie Larkin Ireland 18 477 1.1× 318 1.0× 60 0.5× 148 1.5× 26 0.3× 32 770
Vincent Denis France 11 393 0.9× 184 0.6× 44 0.4× 126 1.3× 62 0.7× 15 623
Rudi Baron United States 19 753 1.7× 224 0.7× 61 0.5× 105 1.1× 77 0.8× 27 1.1k
Bibiana I. Ferreira Portugal 17 633 1.5× 108 0.4× 44 0.4× 152 1.6× 66 0.7× 34 965
Diane E. Brattain United States 16 731 1.7× 492 1.6× 65 0.6× 229 2.3× 29 0.3× 19 1.1k
Janet E. Davis United States 13 286 0.7× 132 0.4× 87 0.8× 51 0.5× 42 0.5× 17 701

Countries citing papers authored by David E. Modrak

Since Specialization
Citations

This map shows the geographic impact of David E. Modrak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David E. Modrak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David E. Modrak more than expected).

Fields of papers citing papers by David E. Modrak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David E. Modrak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David E. Modrak. The network helps show where David E. Modrak may publish in the future.

Co-authorship network of co-authors of David E. Modrak

This figure shows the co-authorship network connecting the top 25 collaborators of David E. Modrak. A scholar is included among the top collaborators of David E. Modrak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David E. Modrak. David E. Modrak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gold, David V., Michael Goggins, David E. Modrak, et al.. (2010). Detection of Early-Stage Pancreatic Adenocarcinoma. Cancer Epidemiology Biomarkers & Prevention. 19(11). 2786–2794. 35 indexed citations
2.
Modrak, David E., et al.. (2009). Detection of early-stage pancreatic carcinoma. Journal of Clinical Oncology. 27(15_suppl). 4613–4613. 16 indexed citations
3.
Modrak, David E., et al.. (2009). Ceramide Regulates Gemcitabine-Induced Senescence and Apoptosis in Human Pancreatic Cancer Cell Lines. Molecular Cancer Research. 7(6). 890–896. 54 indexed citations
4.
Gold, David V., Zarir E. Karanjawala, David E. Modrak, David M. Goldenberg, & Ralph H. Hruban. (2007). PAM4-Reactive MUC1 Is a Biomarker for Early Pancreatic Adenocarcinoma. Clinical Cancer Research. 13(24). 7380–7387. 79 indexed citations
5.
Modrak, David E., David V. Gold, & David M. Goldenberg. (2006). Sphingolipid targets in cancer therapy. Molecular Cancer Therapeutics. 5(2). 200–208. 114 indexed citations
6.
Gold, David V., et al.. (2006). Evaluation of a novel MUC1 biomarker/target antigen for pancreatic cancer. Journal of Clinical Oncology. 24(18_suppl). 4096–4096. 3 indexed citations
7.
Modrak, David E.. (2005). Measurement of Ceramide and Sphingolipid Metabolism in Tumors: Potential Modulation of Chemotherapy. Humana Press eBooks. 111. 183–194. 4 indexed citations
8.
Gold, David V., David E. Modrak, Zhiliang Ying, et al.. (2005). New MUC1 Serum Immunoassay Differentiates Pancreatic Cancer From Pancreatitis. Journal of Clinical Oncology. 24(2). 252–258. 113 indexed citations
9.
Modrak, David E., et al.. (2005). Identification of a Mu-9 (anti-colon-specific antigen-p)-reactive peptide having homology to CA125 (MUC16). International Journal of Oncology. 26(6). 1591–6. 1 indexed citations
10.
Cardillo, Thomas M., Habibe Karacay, David M. Goldenberg, et al.. (2004). Improved Targeting of Pancreatic Cancer. Clinical Cancer Research. 10(10). 3552–3561. 27 indexed citations
11.
Modrak, David E., et al.. (2004). Synergistic Interaction between Sphingomyelin and Gemcitabine Potentiates Ceramide-Mediated Apoptosis in Pancreatic Cancer. Cancer Research. 64(22). 8405–8410. 51 indexed citations
12.
Blumenthal, Rosalyn D., et al.. (2003). An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: Effects of p53 expression. International Journal of Cancer. 108(2). 293–300. 13 indexed citations
13.
Modrak, David E., David V. Gold, D M Goldenberg, & Rosalyn D. Blumenthal. (2003). Colonic Tumor CEA, CSAp and MUC-1 Expression following Radioimmunotherapy or Chemotherapy. Tumor Biology. 24(1). 32–39. 24 indexed citations
14.
Gold, David V., Keith Schutsky, David E. Modrak, & Thomas M. Cardillo. (2003). Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer.. PubMed. 9(10 Pt 2). 3929S–37S. 35 indexed citations
15.
Modrak, David E., et al.. (2002). Sphingomyelin enhances chemotherapy efficacy and increases apoptosis in human colonic tumor xenografts. International Journal of Oncology. 20(2). 379–84. 31 indexed citations
16.
Modrak, David E., et al.. (2000). Sphingomyelin Potentiates Chemotherapy of Human Cancer Xenografts. Biochemical and Biophysical Research Communications. 268(2). 603–606. 24 indexed citations
17.
Modrak, David E., Michael P. Draper, & Stuart B. Levy. (1997). Emergence of Different Mechanisms of Resistance in the Evolution of Multidrug Resistance in Murine Erythroleukemia Cell Lines. Biochemical Pharmacology. 54(12). 1297–1306. 3 indexed citations
18.
Nair, Sandhya, et al.. (1997). Differential changes in genome structure and expression of the mdr gene family in multidrug-resistant murine erythroleukemia cell lines.. PubMed. 9(4). 183–91. 4 indexed citations
19.
Modrak, David E. & John P. Richardson. (1994). The RNA-Binding Domain of Transcription Termination Factor Rho:Isolation, Characterization, and Determination of Sequence Limits. Biochemistry. 33(27). 8292–8299. 37 indexed citations
20.
Modrak, David E., Licia N.Y. Wu, John A. Alberta, & Ronald R. Fisher. (1988). Conformational features of bovine heart mitochondrial transhydrogenase. Biochemistry. 27(20). 7665–7671. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Katherine Kravik Breakdown of academic impact, for papers by Yoshiyuki Nishikawa Breakdown of academic impact, for papers by Shou-Ching Tang Breakdown of academic impact, for papers by Svein A. Carlsen Breakdown of academic impact, for papers by Annemarie Larkin Breakdown of academic impact, for papers by Vincent Denis Breakdown of academic impact, for papers by Rudi Baron Breakdown of academic impact, for papers by Bibiana I. Ferreira Breakdown of academic impact, for papers by Diane E. Brattain Breakdown of academic impact, for papers by Janet E. Davis
Rankless by CCL
2026